Skip to main content
. 2020 Jun 4;21(11):4026. doi: 10.3390/ijms21114026

Figure 2.

Figure 2

Evaluation of clonogenic growth (A) and BrdU incorporation (B) under short-term application of 0.5 nM everolimus (E) or 2.5 µM sulforaphane (S) or 0.5 nM everolimus + 2.5 µM sulforaphane (E + S). Control cells (C) remained untreated. RT112 clones were counted at day 8 and TCCSUP at day 10 following incubation. UMUC3 cells did not form clones (n.c.- not counted). The BrdU assay was carried out with synchronized cells with untreated control cells set at 100%. * indicates significant difference to untreated controls. # indicates significant difference between the mono and the combined applications.